Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

248
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
248
Routh-Hurwitz Criterion I01:15

Routh-Hurwitz Criterion I

562
Consider an electrical power grid, where stability is essential to prevent blackouts. The Routh-Hurwitz criterion is a valuable tool for assessing system stability under varying load conditions or faults. By analyzing the closed-loop transfer function, the Routh-Hurwitz criterion helps determine whether the system remains stable.
To apply the Routh-Hurwitz criterion, a Routh table is constructed. The table's rows are labeled with powers of the complex frequency variable s, starting from the...
562
Routh-Hurwitz Criterion II01:19

Routh-Hurwitz Criterion II

994
In the application of the Routh-Hurwitz criterion, two specific scenarios can arise that complicate stability analysis.
The first scenario occurs when a singular zero appears in the first column of the Routh table. This situation creates a division by zero issues. To resolve this, a small positive or negative number, denoted as epsilon (∈), is substituted for the zero. The stability analysis proceeds by assuming a sign for ∈. If ∈ is positive, any sign change in the first...
994
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

352
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
352
Potential-Energy Criterion for Equilibrium01:16

Potential-Energy Criterion for Equilibrium

932
Potential energy or potential function plays an essential role in determining the stability of a mechanical system. If a system is subjected to both gravitational and elastic forces, the potential function of the system can be expressed as the algebraic sum of gravitational and elastic potential energy. If the system is in equilibrium and is displaced by a small amount, then the work done on the system equals the negative of the change in the system's potential energy from the initial to the...
932
Accelerators01:17

Accelerators

278
Accelerators in concrete serve as admixtures to speed up the hardening process, enabling the concrete to achieve early strength faster. Although accelerators do not necessarily impact the time it takes concrete to set, they reduce this time in practice. A common accelerator is calcium chloride, which is particularly useful for hastening early strength development in cold weather or for rapid repair jobs that require quick heat generation after mixing.
The effectiveness of calcium chloride can...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis.

Statistical methods in medical research·2026
Same author

On the Interplay Between Prior Weight and Variance of the Robustification Component in Robust Mixture Prior Bayesian Dynamic Borrowing Approach.

Statistics in medicine·2026
Same author

Computationally Efficient Approach to Operational Prior Specification in Phase I Clinical Trials.

Statistics in medicine·2026
Same author

Modern Clinical Trials: Seamless Designs and Master Protocols.

Cancer medicine·2026

Related Experiment Video

Updated: Jan 24, 2026

Application of Passive Head Motion to Generate Defined Accelerations at the Heads of Rodents
05:04

Application of Passive Head Motion to Generate Defined Accelerations at the Heads of Rodents

Published on: July 21, 2022

2.2K

Dual-Criterion Approach Incorporating Historical Information to Seek Accelerated Approval With Application in

Marco Ratta1,2, Gaëlle Saint-Hilary2, Valentine Barboux3

  • 1Department of Mathematical Sciences, Polytechnic University of Turin, Turin, Italy.

Statistics in Medicine
|January 23, 2026
PubMed
Summary
This summary is machine-generated.

Accelerated Approvals (AAs) speed up novel treatments using surrogate endpoints. This study proposes an adaptive design to improve AA success rates by linking surrogate and primary endpoints, reducing risks for ineffective treatments.

Keywords:
accelerated approvalgroup sequential designhistorical dataprobability of successsurrogate endpoint

More Related Videos

A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

7.8K
Applications of EEG Neuroimaging Data: Event-related Potentials, Spectral Power, and Multiscale Entropy
11:15

Applications of EEG Neuroimaging Data: Event-related Potentials, Spectral Power, and Multiscale Entropy

Published on: June 27, 2013

34.4K

Related Experiment Videos

Last Updated: Jan 24, 2026

Application of Passive Head Motion to Generate Defined Accelerations at the Heads of Rodents
05:04

Application of Passive Head Motion to Generate Defined Accelerations at the Heads of Rodents

Published on: July 21, 2022

2.2K
A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

7.8K
Applications of EEG Neuroimaging Data: Event-related Potentials, Spectral Power, and Multiscale Entropy
11:15

Applications of EEG Neuroimaging Data: Event-related Potentials, Spectral Power, and Multiscale Entropy

Published on: June 27, 2013

34.4K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Drug Development

Background:

  • Accelerated Approvals (AAs) enable early access to novel treatments for life-threatening diseases based on surrogate endpoints.
  • A significant number of conditionally approved treatments fail to gain full approval due to a lack of correlation between surrogate and primary endpoints.

Purpose of the Study:

  • To develop an improved adaptive group sequential design for Accelerated Approvals.
  • To enhance the reliability of AAs by incorporating a predictive metric for the primary endpoint and leveraging historical data.

Main Methods:

  • Propose a novel adaptive group sequential design with an early dual-criterion interim analysis for AA.
  • Incorporate historical information borrowing, including historical control data and the surrogate-primary endpoint relationship.
  • Develop metrics to assess the risks of correct and incorrect early AAs and control the family-wise error rate (FWER).

Main Results:

  • The proposed design allows for explicit control of AA-related risks, including FWER.
  • The methodology was evaluated through a simulation study, demonstrating its potential utility.
  • The approach aims to balance the need for timely drug access with patient safety and regulatory certainty.

Conclusions:

  • The novel adaptive design offers a robust framework for optimizing Accelerated Approvals.
  • Integrating predictive metrics and historical data can improve the accuracy and success rate of AAs.
  • This approach supports regulatory decision-making for novel therapeutics, particularly in areas like metastatic colorectal cancer.